A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors

Trial Profile

A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs PCA 062 (Primary)
  • Indications Breast cancer; Head and neck cancer; Oesophageal cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 18 Jul 2017 Planned End Date changed from 25 Jun 2018 to 25 Dec 2018.
    • 18 Jul 2017 Planned primary completion date changed from 15 Jun 2017 to 14 Jun 2018.
    • 17 Apr 2017 Planned number of patients changed from 75 to 90.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top